Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patie…

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06422806

Phase 3

Comparing Treatment With Versus Without Neoadjuvant Doxorubicin and Ifosfamide in Selected Patients With High-Risk Resectable Soft-Tissue Sarcoma

This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrol…

Resectable LiposarcomaResectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic Sarcoma

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07823491

Phase 1

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05711615

Phase 1

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this …

Solid TumoursSarcomaHNSCC+12 more

A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma

The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, del…

SarcomaMyxofibrosarcomaUndifferentiated Pleomorphic Sarcoma+1 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04332874

Observational

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablatio…

Undifferentiated Pleomorphic Sarcoma

Estimated

~$10 – $7,500

Matthew BucknorNCT04123535